Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Faron Pharmaceuticals (FARN) Share Price

Price 190.00p on 25-03-2025 at 17:30:01
Change -2.50p -1.3%
Buy 195.00p
Sell 185.00p
Buy / Sell FARN Shares
Last Trade: Sell 2.00 at 185.00p
Day's Volume: 1,682
Last Close: 190.00p
Open: 190.00p
ISIN: FI4000153309
Day's Range 190.00p - 190.00p
52wk Range: 89.00p - 270.00p
Market Capitalisation: £212m
VWAP: 190.80262p
Shares in Issue: 112m

Faron Pharmaceuticals (FARN) Latest Trades

Buy/Sell Volume Trade Prc Trade Type Trade Time
Sell* 2 185.00p SI Trade
15:18:34 - 25-Mar-25
Buy* 385 192.00p Ordinary
15:12:00 - 25-Mar-25
Unknown* 1,000 190.00p Ordinary
15:02:50 - 25-Mar-25
Buy* 295 192.00p Ordinary
14:57:54 - 25-Mar-25
Sell* 1,939 192.3661p Ordinary
16:13:25 - 24-Mar-25
Unknown* 5,445 191.666p Ordinary
11:53:55 - 24-Mar-25
Unknown* 10,000 193.00p Negotiated Trade
10:39:13 - 24-Mar-25
Unknown* 4,743 187.666p Ordinary
09:54:05 - 24-Mar-25
Unknown* 5,000 187.666p Ordinary
09:42:37 - 24-Mar-25
Buy* 513 193.00p Ordinary
08:44:55 - 24-Mar-25
See more Faron Pharmaceuticals trades

Faron Pharmaceuticals (FARN) Share Price History

Time period:
to
Date Open High Low Close Volume
25th Mar 2025 (Tue) 190.00 190.00 190.00 190.00 1,682
24th Mar 2025 (Mon) 190.00 192.50 190.00 192.50 27,690
21st Mar 2025 (Fri) 190.00 192.50 190.00 190.00 17,647
20th Mar 2025 (Thu) 187.50 190.00 187.50 190.00 9,756
19th Mar 2025 (Wed) 185.00 190.00 185.00 187.50 10,780
18th Mar 2025 (Tue) 182.50 185.00 182.50 185.00 14,134
17th Mar 2025 (Mon) 180.00 190.00 180.00 182.50 11,585
14th Mar 2025 (Fri) 172.50 182.50 172.50 182.50 75,608
13th Mar 2025 (Thu) 172.50 175.00 172.50 172.50 591
12th Mar 2025 (Wed) 172.50 172.50 172.50 172.50 8,061
11th Mar 2025 (Tue) 172.50 172.50 172.50 172.50 4,166
10th Mar 2025 (Mon) 171.50 175.00 171.50 172.50 3,475
7th Mar 2025 (Fri) 171.50 167.00 167.00 167.00 16,082
6th Mar 2025 (Thu) 176.50 176.50 171.50 171.50 14,705
5th Mar 2025 (Wed) 176.50 176.50 176.50 176.50 1,884
4th Mar 2025 (Tue) 178.00 178.00 176.50 176.50 14,027
3rd Mar 2025 (Mon) 170.00 175.00 175.00 175.00 43,633
28th Feb 2025 (Fri) 172.50 172.50 170.00 170.00 10,499
27th Feb 2025 (Thu) 165.00 175.00 170.00 172.50 28,444
26th Feb 2025 (Wed) 167.50 170.00 170.00 170.00 10,781
25th Feb 2025 (Tue) 170.00 170.00 167.50 167.50 4,481
See more Faron Pharmaceuticals price history

Faron Pharmaceuticals (FARN) Regulatory News

Date Source Headline
3rd Mar 2025 12:05 pm RNS FDA Grants Orphan Drug Designation
28th Feb 2025 12:00 pm RNS Notice of Annual General Meeting
27th Feb 2025 7:30 am RNS Positive EMA Opinion on Orphan Drug Designation
27th Feb 2025 7:15 am RNS Annual Report 2024 published
27th Feb 2025 7:00 am RNS Financial Statement 1 January to 31 December 2024
19th Feb 2025 10:00 am RNS Notice of Financial Statement and Annual Report
14th Feb 2025 12:00 pm RNS Holding(s) in Company
11th Feb 2025 7:30 am RNS Change of Broker
6th Feb 2025 3:00 pm RNS Holding(s) in Company
6th Feb 2025 7:00 am RNS Results of Oversubscribed Placing
See more Faron Pharmaceuticals regulatory news

Faron Pharmaceuticals (FARN) Share News

UK shareholder meetings calendar - next 7 days

14th Mar 2025 14:09

Read More

UK earnings, trading statements calendar - next 7 days

20th Feb 2025 14:16

Read More

Faron Pharmaceuticals raises EUR12 million from oversubscribed placing

6th Feb 2025 11:41

(Alliance News) - Faron Pharmaceuticals Ltd on Thursday said it has raised EUR12 million from an oversubscribed placing ahead of upcoming trial results. Read More

IN BRIEF: Faron Pharmaceuticals shares up as presents data on Bexmab

10th Dec 2024 14:31

Faron Pharmaceuticals PLC on Tuesday - Turku, Finland-based developer of cancer immunotherapies - Presents full analysis of positive phase 2 interim data from Bexmab trial at the annual meeting of the Society of Hematology in San Diego. Faron highlights an overall response rate of 80% in refractory or relapsed HMA failed MDS patient population. HMA stands for hypomethylating agents, while MDS stands for myelodysplastic syndromes. Chief Executive Officer Juho Jalkanen says: "With this compelling evidence, we are well positioned to advance to the full phase 2 efficacy readout and actively pursue further regulatory interactions to navigate and refine the pivotal pathway for BLA filing." Read More

Faron announces promising findings from blood cancer drug trial

27th Nov 2024 11:29

(Alliance News) - Faron Pharmaceuticals Ltd on Wednesday reported positive data from an ongoing trial on patients receiving a new treatment for a rare blood cancer. Read More

See more Faron Pharmaceuticals news
FTSE 100 Latest
Value8,663.80
Change25.79

Login to your account

Forgot Password?

Not Registered